TrialClinical cancer research : an official journal of the American Association for Cancer Research2015

TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.

Andres Forero-Torres et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.